Literature DB >> 25574087

Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.

Ariolana A Dos Santos1, Adriana A Carvalho1.   

Abstract

The optimal therapy for Helicobacter pylori (H. pylori) infection should combine a high cure rate and a short treatment duration with a favorable side-effect profile and should maintain a low cost. Several strategies have been proposed to increase the H. pylori eradication rate, including the extension of the treatment duration to 14 d, the use of a four-drug regimen (quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as levofloxacin. However, triple therapy remains the most widely accepted first-line treatment regimen in Brazil and the United States and throughout Europe. Because this therapy is limited by resistance to clarithromycin, other therapeutic regimens have been investigated worldwide. This review describes the current literature involving studies directly comparing these different therapies and their efficacies.

Entities:  

Keywords:  Clarithromycin resistant; Helicobacter pylori; Peptic ulcers; Treatment; Triple therapy

Mesh:

Substances:

Year:  2015        PMID: 25574087      PMCID: PMC4284330          DOI: 10.3748/wjg.v21.i1.139

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

1.  Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis.

Authors:  Ayse Demet Kaya; C Elif Oztürk; Yusuf Akcan; Mustafa Behçet; A Esra Karakoç; Mihriban Yücel; Müge Mısırlıoglu; Serdar Tuncer
Journal:  Curr Ther Res Clin Exp       Date:  2007-05

2.  Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital.

Authors:  Jacobo Dib; Bethseidy Alvarez; Liskie Mendez; Maria E Cruz
Journal:  Arab J Gastroenterol       Date:  2013-10-14       Impact factor: 2.076

3.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

4.  Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study.

Authors:  Bilal Ergül; Erdem Koçak; Adnan Taş; Levent Filik; Seyfettin Köklü
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-01-09       Impact factor: 2.947

Review 5.  Treatment of Helicobacter pylori.

Authors:  K Wolle; P Malfertheiner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2007       Impact factor: 3.043

Review 6.  Diagnosis and treatment of Helicobacter pylori infection.

Authors:  Peter Bytzer; Jens Frederik Dahlerup; Jens Ravn Eriksen; Dorte Ejg Jarbøl; Steffen Rosenstock; Signe Wildt
Journal:  Dan Med Bull       Date:  2011-04

7.  The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation.

Authors:  H Zojaji; R Talaie; D Mirsattari; M Haghazali; M Molaei; N Mohsenian; F Derakhshan; M R Zali
Journal:  Dig Liver Dis       Date:  2009-06-02       Impact factor: 4.088

8.  Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.

Authors:  Ping-I Hsu; Deng-Chyang Wu; Wen-Chi Chen; Hui-Hwa Tseng; Hsien-Chung Yu; Huay-Min Wang; Sung-Shuo Kao; Kwok-Hung Lai; Angela Chen; Feng-Woei Tsay
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

9.  Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.

Authors:  Kevin S H Liu; Ivan F N Hung; W K Walter Seto; Teresa Tong; Axel S J Hsu; Frank Y F Lam; David Y K But; S Y Wong; Wai K Leung
Journal:  Gut       Date:  2013-12-02       Impact factor: 23.059

10.  Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population.

Authors:  Seyedali Seyedmajidi; Dariush Mirsattari; Homayoun Zojaji; Elahe Zanganeh; Mohammadreza Seyyedmajidi; Shohreh Almasi; Mohammadreza Zali
Journal:  Arab J Gastroenterol       Date:  2013-01-25       Impact factor: 2.076

View more
  8 in total

1.  Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.

Authors:  Ayse Kefeli; Sebahat Basyigit; Abdullah Ozgur Yeniova; Tarık Tayfur Kefeli; Muzaffer Aslan; Ozlem Tanas
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

Review 2.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

Review 3.  Helicobacter pylori colonization of the oral cavity: A milestone discovery.

Authors:  John K C Yee
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 4.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 5.  The Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis.

Authors:  Juan Wang; Wen-Ting Li; Yi-Xiang Zheng; Shu-Shan Zhao; Ning Li; Yan Huang; Rong-Rong Zhou; Ze-Bing Huang; Xue-Gong Fan
Journal:  Gastroenterol Res Pract       Date:  2016-01-24       Impact factor: 2.260

Review 6.  Bacteriophages of Helicobacter pylori.

Authors:  Angela B Muñoz; Johanna Stepanian; Alba Alicia Trespalacios; Filipa F Vale
Journal:  Front Microbiol       Date:  2020-11-12       Impact factor: 5.640

7.  GC-MS Profiling, Anti-Helicobacter pylori, and Anti-Inflammatory Activities of Three Apiaceous Fruits' Essential Oils.

Authors:  Hatun A Alomar; Noha Fathallah; Marwa M Abdel-Aziz; Taghreed A Ibrahim; Wafaa M Elkady
Journal:  Plants (Basel)       Date:  2022-10-05

8.  ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Authors:  Stanley L Marks; Peter H Kook; Mark G Papich; M K Tolbert; Michael D Willard
Journal:  J Vet Intern Med       Date:  2018-10-31       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.